Search clinical trials for: Placebo to remibrutinib

Total 60520 results

Novartis Pharmaceuticals

Terminated

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe)

Sjögren Syndrome

Spain, United States, Belgium, Hungary, Germany, Switzerland, Australia, Denmark, China, Taiwan, United Kingdom, Bulgaria
Novartis Pharmaceuticals

Recruiting

A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.

Chronic Spontaneous Urticaria

Switzerland, Australia, Italy, Spain, France, Germany, Korea, Republic of, Netherlands, Taiwan, India, Czechia, Hungary, Thailand, Turkey, Malaysia, Canada, Argentina, Bulgaria, Slovakia, Brazil, Poland
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines (REMIX-1)

Chronic Spontaneous Urticaria

United States, Hungary, Taiwan, Spain, Italy, Korea, Republic of, Australia, France, Bulgaria, Czechia, Turkey, India, Argentina, Mexico, Japan, Colombia, Russian Federation, Puerto Rico, Singapore
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines (REMIX-2)

Chronic Spontaneous Urticaria

United States, India, Malaysia, Taiwan, Poland, United Kingdom, China, Thailand, Switzerland, Germany, Vietnam, Brazil, Russian Federation, Slovakia, Denmark, Canada, South Africa, Austria
Novartis Pharmaceuticals

Recruiting

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Chronic Spontaneous Urticaria

United States, Korea, Republic of, Spain, France, Germany, Bulgaria, United Kingdom, China, Hungary, Czechia, Turkey, Argentina, Colombia, Italy, Denmark, Japan, Taiwan, Australia, Singapore, Switzerland, Russian Federation, Thailand and more
Novartis Pharmaceuticals

Recruiting

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Allergy, Peanut

United States, Spain
Novartis Pharmaceuticals

Recruiting

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Chronic Spontaneous Urticaria

United States, Singapore, Spain, Germany, Turkey, Italy, Hong Kong, China, Argentina, Malaysia, Thailand, Poland, Japan, Netherlands, Chile, Canada
Novartis Pharmaceuticals

Completed

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Chronic Spontaneous Urticaria

Spain, Germany, France, Korea, Republic of, Turkey, Argentina, Slovakia, United States, Canada, Singapore
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines (BISCUIT)

Chronic Spontaneous Urticaria

Japan
Novartis Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Hepatic Impairment

Hungary
Novartis Pharmaceuticals

Recruiting

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Chronic Inducible Urticaria

China, United States, Australia, Korea, Republic of, Israel, Turkey, Hong Kong, Japan, Argentina, Malaysia, Singapore, Thailand, Canada
Alyatec

Completed

Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber

Allergic Rhinitis | Rhinoconjunctivitis | Allergy to Pollen

France
Noema Pharma AG

Recruiting

Basimglurant in Children, Adolescents, and Young Adults With TSC

Tuberous Sclerosis Complex

United States, India, Israel, Turkey, Italy, Poland, Spain, United Kingdom
Novartis Pharmaceuticals

Available

Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Spain, France, United States, Austria, Germany, Hungary, Belgium, Iceland, Netherlands, Denmark, Czechia
CoMentis
Alpharmagen, Inc.

Suspended

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Schizophrenia

United States
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

Obesity

United States
ReveraGen BioPharma, Inc.
Santhera Pharmaceuticals

Recruiting

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Becker Muscular Dystrophy

United States, Italy
Novartis Pharmaceuticals

Active, not recruiting

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Cardiovascular Disease and Lipoprotein(a)

United States, China, Germany, South Africa, Italy, Spain, Belgium, Czechia, Hungary, Japan, Taiwan, Netherlands, Australia, Austria, Canada, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Argentina, Denmark, Greece, Romani... and more
AstraZeneca

Not yet recruiting

A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma (ARTEMISIA)

Asthma

Canada, Denmark, Germany, Spain, United Kingdom
Bayer

Not yet recruiting

A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure

Chronic Kidney Disease | Arterial Hypertension | Non-proliferative Diabetic Retinopathy

Germany
KalVista Pharmaceuticals, Ltd.

Completed

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (ACI)

Knee Cartilage Lesion

Austria
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

Healthy

United Kingdom
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Hypertension

China
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
Bayer

Recruiting

A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis (SIRIUS)

Thrombolysis | Symptomatic Proximal Deep Vein Thrombosis

Belgium, France, Italy, Netherlands, Canada, Germany, Czechia
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

Asthma

United States, Belgium, Germany, Israel, Argentina, France, Denmark, Slovakia
KalVista Pharmaceuticals, Ltd.

Completed

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
Cardior Pharmaceuticals GmbH

Active, not recruiting

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction (HF-REVERT)

Myocardial Infarction, Acute | Heart Failure, Left Sided

Netherlands, Spain, Hungary, Germany, United Kingdom, Czechia, Poland, Greece
Bayer

Completed

A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses

Hypertension | Chronic Kidney Disease

Germany, Bulgaria
AstraZeneca

Completed

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease | Lung Disease

Bulgaria, Slovakia
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Pharmacokinetics | Safety | Pharmacodynamics of AZD7594

United Kingdom
University of Maryland, Baltimore
Bill and Melinda Gates Foundation

Active, not recruiting

Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali (SANTE)

Stillbirths and Infant Mortality

Mali
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
Texas Tech University
EHP Labs

Completed

Metabolic Effects of a Thermogenic Ready-to-drink Beverage

Metabolism | Metabolic Rate

United States
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Lohocla Research Corporation
National Institute on Drug Abuse (NIDA)

Recruiting

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

Chronic Pain

United States
Novartis Pharmaceuticals

Terminated

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Part 1 - Healthy Volunteers | Part 2 - Patients With Hypertension

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I) (AUGUST I)

Rheumatoid Arthritis

United States, Canada
Harvard University

Withdrawn

Mindfulness Intervention and Symptom Variability in Hearing

Hearing Loss

United States
AstraZeneca

Completed

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Schizophrenia

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
Xencor, Inc.
PPD; ICON plc

Completed

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Subjects With Optic Neuritis

Optic Neuritis

United States, France, Spain, United Kingdom, Canada, Germany, Czech Republic, Belgium, Australia, Switzerland, Lebanon
Merck Sharp & Dohme LLC

Completed

A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Osteoporosis
Merck Sharp & Dohme LLC

Terminated

A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)

Type 2 Diabetes Mellitus

Search clinical trials for: Placebo to remibrutinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations